Overall verdict
Neutral
6.2/10
1-year performance
+40.43%
Score breakdown
Up 40.4% over 1 year, 90% of the 52-week range.
Strongest: Financial strength 10.0/10. Weakest: Shareholder return 4.4/10.
28 analysts, target +0.0% vs the price.
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines to treat various diseases worldwide. The company develops product candidates to treat eye, allergic and inflammatory, cardiovascular, metabolic, neurological, infectious, and rare diseases; and cancer, hematologic conditions. It also offers EYLEA injections for wet age-related macular degeneration and diabetic macular edema ;
myopic choroidal neovascularization ; diabetic retinopathy ; neovascular glaucoma ; retinopathy of prematurity ; Dupixent injection to treat atopic dermatitis and asthma ; Libtayo injection for metastatic or locally advanced cutaneous squamous cell carcinoma ; Praluent injection to treat heterozygous familial hypercholesterolemia (HoFH) ; and Kevzara solution for rheumatoid arthritis. It has license and collaboration agreement with Bayer for the development and commercialization of EYLEA 8 mg and EYLEA ;
Alnylam Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for diseases by addressing therapeutic disease targets expressed in eye and central nervous system ; Intellia Therapeutics, Inc. to advance CRISPR/Cas9 gene-editing technology for in vivo therapeutic development for therapies focused on neurological and muscular diseases ; Hansoh Pharmaceuticals Group Company Limited to acquire development and commercial rights for HS-20094, a dual GLP-1/GIP receptor ;
and Tessera Therapeutics, Inc. develops and commercializes TSRA-196, an investigational gene editing therapy for Alpha-1 antitrypsin deficiency. The company has a strategic collaboration with Telix Pharmaceuticals Limited to develop and commercialize radiopharmaceutical therapies. It also has a strategic collaboration with CytomX Therapeutics, Inc. to create conditionally-activated bispecific cancer therapies. It has a strategic alliance with Sanofi to develop long-acting immunology antibodies. The company was incorporated in 1988 and is based in Tarrytown, New York.
Sector
Health Care
Industry
Biotechnology
Primary listing
Nasdaq
United States
CEO
Leonard Schleifer
Founded
1988
Employees
15 410
Revenue / employee
930 753 USD
Next earnings
February 1, 2027 (estimated)
Institutional holders
- GEODE CAPITAL MANAGEMENT, LLC2.55%
- FMR LLC1.00%
- Bank of New York Mellon Corp0.71%
- Rest of the register95.74%
3 13F filings as of September 30, 2026: US managers above $100M, filed up to 45 days after quarter end. No insiders, no retail. A share on loan is declared by its lender and by whoever bought it from the short seller, so the total can exceed 100%.
Research uses the underlying stock’s market history. The purchase quote is calculated separately when you review your order.
52-week high
991.73 USD
52-week low
591.52 USD
1-year performance
40.43%
Rising
Year-to-date performance
23.13%
Rising
Drawdown
-3.87%
Near its high
Position in the 52-week range
90% of range
Against the world ETF
Over 26 years, from December 2000 to October 2026, the share did not clearly beat the world ETF once risk is accounted for. It earned much more, but shaking 3.7 times harder: once that risk is counted, it did about as well as the ETF.
$10,000 placed at the end of December 2000 are worth today
| Regeneron | $265,598 |
| World ETF | $65,117 |
| S&P 500 | $91,204 |
| Risk-free placement | $15,894 |
The risk
- Shaking:the share moves 3.7 times as much as the world ETF.
- Worst fall:-86 % between December 2000 and March 2005. $10,000 placed at the top fell to $1,449. The world ETF, at worst: -53 %. Back to its high in 71 months.
Regeneron earned 4 times as much as the world ETF since 2000
Value of $10,000 placed at the end of December 2000, dividends reinvested, in dollars
- Regeneron: $265,598
- World ETF: $65,117
- S&P 500: $91,204
- Risk-free placement: $15,894
Based on past performance. This is not a recommendation.
Range: 921.23 USD - 1008.60 USD (3 methods agree)
The price implies growth of 8.31% per year; the company grows at 6.33%.
Gross margin 82.7%, net margin 28.5%, ROIC 13.9%, ROE 14.9%.
Net margin
28.51%
High
Sector -14.06%|S&P 13.40%
Gross margin
82.74%
Fair
Return on equity (ROE)
14.95%
Fair
Sector -18.81%|S&P 17.06%
Return on invested capital (ROIC)
13.93%
Fair
Free cash flow margin (FCF)
22.65%
High
Profit-to-cash conversion (FCF conversion)
0.79x
High
Margin stability
9.8 pts
Uneven
Revenue to net income
Growth
5.4/10Revenue up 36.3% over 1 year, 11.0% a year over 5, EPS 6.3% a year over 5.
Revenue (trailing 12 months)
16.9Md USD
Revenue growth (1y)
36.27%
Hyper-growth
Revenue growth (3y)
17.83%
Solid
EPS growth (1y)
35.49%
Strong
EPS CAGR (5y)
6.33%
Low
EPS revisions (3 months)
29.70%
Sharply revised up
Valuation
5.4/10P/E 21.0x, forward P/E 16.1x, EV/EBITDA 17.3x, PEG 3.33. The multiple sits in the 80th percentile of its own 5-year history.
P/E (TTM)
21.0x
Fair
Sector 32.5x|S&P 23.6x
Forward P/E
16.1x
Fair
EV / EBITDA
17.3x
Fair
Sector 18.0x|S&P 15.5x
PEG
3.33
Very expensive
Sector 0.88|S&P 0.91
Fair value (reverse DCF)
973.46 USD
Fairly priced
P/E vs its own 5-year history
among the 20% highest valuations
At its historical high
Market cap
98.6Md USD
Financial strength
10.0/10Cash covers 344.1% of the debt, net debt/EBITDA -1.3x.
Net debt / EBITDA
-1.3x
Net cash
Gearing (net debt / equity)
-19.72%
Net cash
Cash
9.3Md USD
Cash / market cap
9.45%
Solid
Cash / total debt
344.06%
Net cash
Interest coverage
104.2x
Very solid
Net debt
-6.6Md USD
Equity
33.5Md USD
Closed daily candles, 2 years
Last close on November 10, 2026: 916.06 USD
- MM20853.82
- MM50809.23
- MM200743.93
- RSI 1464.3
Top panel: closed candles, 20, 50 and 200-day moving averages, with volume in grey. Bottom panel: 14-day RSI with dashed 30 and 70 levels.
200-day average slope, 1 month
+1.15%
200-day average slope, 3 months
+3.62%
50-day average slope, 1 month
+2.47%
Price structure
higher-low
Bullish RSI divergence
No
20-day volatility
3.50 % per day
Volatility change
+72.88%
Forecasts by fiscal year
| Fiscal year | EPS | Normalised EPS | Revenue | EBITDA | Net income |
|---|---|---|---|---|---|
| 2026 | 59.27 (10) | 68.75 (25) | 18 783 (25) | 8 533 (5) | 6 426 (9) |
| 2027 | 62.12 (10) | 70.72 (27) | 20 150 (24) | 9 355 (5) | 6 560 (9) |
Amounts in millions of USD, EPS in USD per share. In brackets, the number of analysts. Consensus as of November 10, 2026.
Same sub-industry: 416 companies behind the medians.
| # | Company | Code | Country | Overall / 10 | Fundamentals / 10 | Mkt cap | P/E | Net margin | Revenue growth | ROIC | Net debt / EBITDA | FCF yield | 1-year perf. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | ARGX | 6.6 | 6.1 | 60.3Md USD | 38.9x | 32.8 % | 81.8 % | 23.3 % | -4.1x | 1.8 % | 16.9 % | ||
| 2 | ONC | 6.6 | 6.6 | 47.2Md USD | 53.2x | 13.9 % | 34.0 % | 14.5 % | -4.4x | 3.1 % | 25.7 % | ||
| 3 | REGN | 6.2 | 6.1 | 98.6Md USD | 21.0x | 28.5 % | 36.3 % | 13.9 % | -1.3x | 3.9 % | 40.4 % | ||
| 4 | ABBV | 6.1 | 5.0 | 521Md USD | 50.8x | 15.6 % | 10.3 % | 16.1 % | 2.2x | 3.6 % | 34.7 % | ||
| 5 | VRTX | 5.6 | 4.1 | 139Md USD | 35.2x | 30.5 % | 10.4 % | 17.5 % | -0.9x | 2.3 % | 29.2 % | ||
| 6 | AMGN | 5.5 | 5.3 | 253Md USD | 27.2x | 24.1 % | 8.1 % | 14.7 % | 2.9x | 3.8 % | 44.7 % | ||
| 7 | CSL | 4.6 | 3.7 | 65.9Md USD | Not meaningful (loss) | -15.6 % | -2.8 % | -8.9 % | 1.8x | 4.3 % | 14.8 % | ||
| 8 | GILD | 4.2 | 2.9 | 211Md USD | Not meaningful (loss) | -12.4 % | 6.7 % | -9.6 % | 1.1x | 6.5 % | 43.1 % | ||
| 9 | MRNA | 3.3 | 1.3 | 101Md USD | Not meaningful (loss) | -110.5 % | 29.2 % | -26.5 % | 0.4x | -2.0 % | 896.8 % |
